Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00YBZ
|
|||
| Former ID |
DIB016161
|
|||
| Drug Name |
OC-10X
|
|||
| Synonyms |
AMD therapy, OcuCure
Click to Show/Hide
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 1 | [1] | |
| Proliferative diabetic retinopathy [ICD-11: 9B71.01] | Phase 1 | [2] | ||
| Company |
Ocucure therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16N2O
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)C3NC4=CC=CC=C4C(=O)N3
|
|||
| InChI |
1S/C20H16N2O/c23-20-17-8-4-5-9-18(17)21-19(22-20)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,19,21H,(H,22,23)
|
|||
| InChIKey |
XRUAOBKXCFNPCK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023889) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01869933) Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.